Abstract Stereotactic radiosurgery (SRS) is a well-established treatment modality for management of both benign and malignant central nervous tumors. One limiting factor in the use of SRS is tumor size. Staged radiosurgery treatment is an option to utilize this treatment modality while still limiting associated toxicity. This involves treating each target in 2 separate sessions, spaced apart by approximately 30 days. We describe a series of 17 patients with 20 unique lesions treated using this technique in our department from January of 2019 through December of 2021. 18 treated lesions were malignant brain metastases and 2 were meningiomas. For 13 lesions, SRS was the primary treatment, and for 7 lesions, SRS was adjuvant treatment after surgery. The median target size for fraction 1 was 18.40 cm^3 with a median dose of 12.65 Gy. The median target size for fraction 2 was 14.50 cm^3 with a median dose of 12.08 Gy. All but one target was prescribed to the 50% isodose line. Median follow up was 7.12 months. Local control at the site of treated lesions was 90%. 3 patients with local control at the site of the fractionated treatment were noted to have additional progression within the CNS. There were 2 patient deaths within 30 days of treatment. One death was due to respiratory failure. The other cause of death was unknown. Treatment was well tolerated with no grade 3 or higher acute toxicity. 50% of patients went on to receive additional systemic therapy. 55% of patients are known to have died at the time of latest follow up. Overall, staged gamma knife radiosurgery appears to be an effective option for treating both intact and resected tumors with an acceptable toxicity profile.